For the approximately 15% of patients with GC expressing human epidermal growth factor receptor 2 (HER2)/Erb-B2 receptor tyrosine kinase 2 (ERBB2) (9,10), the anti-HER2 monoclonal antibody trastuzumab when added to fluoropyrimidine- and platinum-based chemotherapy offers a targeted therapeutic option. Here, ERBB2 is linked to gastric cancer.